Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - November 2014

Expertise in Neuropharmacology





Autumn News

Presentation at World Orphan Drug Congress, Belgium

Adrian Newman-Tancredi chaired a session at the World Orphan Drug Congress in Brussels, Belgium (12-14 November 2014). The session was entitled "Innovation in the Orphan Drug Sector" and Adrian also give a joint presentation with Dr. Ana Paula Abdala Sheikh of Bristol University, entitled "Targeting Rett syndrome with NLX-101, a novel Orphan Medicinal Product".

Lecture at Caen University, France

Adrian Newman-Tancredi gave an invited lecture at the Caen University Pharmaceutical Sciences Training Faculty in Normandy, France. Adrian was invited by Prof. François Dauphin and presented recent advances in understanding of G-protrein Coupled Receptor signaling, notably the concept of 'biased agonism'. For further information click here.











Neurolixis Update

Neurolixis establishes subsidiary in France

Neurolixis Inc., of which Adrian Newman-Tancredi, PhD, DSc, is co-founder and Chief Scientific Officer, established offices in Castres, France, in order to facilitate collaboration with European research and funding institutions. Neurolixis has rapidly expanded its network of academic and private research collaborations.

See the full press announcement here.

For further information, Contact.


Research grant awarded by Fox Foundation

Adrian Newman-Tancredi is Principal Investigator of a further grant awarded by the Michael J Fox Foundation. The grant supports investigation of a highly selective serotonergic agonist, NLX-112, in animal dosing studies in preparation for a clinical trial in Parkinson's Disease patients suffering from dyskinesias. This is the fourth grant awarded by the Foundation to Neurolixis. For further information click here.


Scientific Communication

Just Published:
(click on links to view Abstracts)

Pinpointing brainstem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists.

Abdala AP, Bissonnette JM, Newman-Tancredi A. Front Physiol. 2014 May 30; 5:205 (FREE PDF).


A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease.
Becker G, Streichenberger N, Billard T, Newman-Tancredi A, Zimmer L. CNS Neurosci Ther. 2014 Oct;20(10):930-4. doi: 10.1111/cns.12306. 



 NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs. 

 NeuroAct Communication is an independent consulting service founded by
Adrian Newman-Tancredi PhD DSc, an experienced pharmaceutical industry professional.

Find out more about Adrian in his Executive Profile